Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5849055 | 0.70 | CRHR1 (0.33) | POLB | |
| SCHEMBL27228493 | 0.69 | MAPT (0.34) | KDM4EALDH1A1LMNAPOLBMAPT | |
| SCHEMBL31352143 | 0.68 | MAPK14 (0.34) | — | |
| SCHEMBL5848414 | 0.67 | CRHR1 (0.41) | — | |
| SCHEMBL14557156 | 0.64 | — | — | |
| SCHEMBL25045802 | 0.63 | DRD2 (0.40) | KDM4E | |
| SCHEMBL22288359 | 0.63 | LMNA (0.36) | LMNATSHR | |
| SCHEMBL19327459 | 0.62 | MAPK14 (0.40) | KDM4EALDH1A1LMNAPOLBMAPT | |
| SCHEMBL31352124 | 0.60 | RECQL (0.38) | TDP1 | |
| SCHEMBL12146432 | 0.60 | USP2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7151109-B2 | Pyrazolo[1,5-a]pyridine derivatives and their use as neurotransmitter modulators | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-12-19 | — | — | US | disclosed |
| EP-1485384-A1 | PYRAZOLO(1,5-A)PYRIDINE DERIVATIVES AS NEUROTRANSMITTER MODULATORS | Pharmacia & Upjohn Company LLC (US) | 2004-12-15 | — | — | EP | disclosed |
| EP-1397340-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-03-17 | — | — | EP | disclosed |
| US-20040002511-A1 | Novel pyrazolo[1,5-a]pyridine derivatives and their use as neurotransmitter modulators | PHARMACIA & UPJOHN COMPANY | 2004-01-01 | — | — | US | disclosed |
| WO-2003078435-A1 | PYRAZOLO(1,5-A)PYRIDINE DERIVATIVES AS NEUROTRANSMITTER MODULATORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2003-09-25 | — | — | WO | disclosed |
| WO-2002098850-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002511-A1 | Novel pyrazolo[1,5-a]pyridine derivatives and their use as neurotransmitter modulators | CRHR1, HTR5A, CRH | ESR1 687/4885ESR2 1114/4885KDM4E 2215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.